Carbamazepine augmentation in depressive patients non-responding to citalopram: A pharmacokinetic and clinical pilot study

European Neuropsychopharmacology

Volumn 12, Issue 3, 2002, Pages 255-260

  Steinacher, Lina ^a   Vandel, Pierre ^b   Zullino, Daniele F ^b   Eap, Chin B ^b   Brawand Amey, Marlyse ^b   Baumann, Pierre ^b  

^a Praxis am Zweierplatz   (Switzerland)

^b HÔPITAL SAINT JACQUES   (France)

Author keywords

Carbamazepine Augmentation; Citalopram; Cytochrome P 450; Depression; Escitalopram; Pharmacokinetic interaction

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CARBAMAZEPINE; CITALOPRAM; CYTOCHROME P450 3A; ESCITALOPRAM; PROPIONIC ACID DERIVATIVE;

ADULT; ALCOHOL ABUSE; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; MALE; NAUSEA; PANIC; PHOBIA; PILOT STUDY; PRIORITY JOURNAL; PROTEIN INDUCTION; RASH; RATING SCALE; SEROTONIN SYNDROME; STEREOCHEMISTRY;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIMANIC AGENTS; CARBAMAZEPINE; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; STATISTICS, NONPARAMETRIC; STEREOISOMERISM;

EID: 0036239878     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(02)00018-4     Document Type: Article

References (50)

1. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients. a clinical, pharmacokinetic, and pharmacogenetic investigation
2. Enantiomeric antidepressant drugs should be considered on individual merit
3. Clin. pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide - An update
4. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19
5. Concomitant intake of nortriptyline and carbamazepine
6. Carbamazepine-induced release of serotonin from rat hippocampus in vitro
7. Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression
8. Lithium addition in treatment-resistant depression
9. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites
10. Antiepileptic drug augmentation for treatment-resistant depression
11. The serotonin syndrome scale: First results on validity
12. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer
13. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service
14. Citalopram [review]
15. Refractory depression. A review with particular reference to the use of lithium augmentation
16. Lack of sertraline efficacy probably due to an interaction with carbamazepine
17. Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography
18. In vitro biotransformation of the selective serotonin reuptake inhibitor citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations
19. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites
20. Carbamazepine-nefazodone interaction in healthy subjects
21. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases
22. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients
23. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine
24. The UKU side effect rating scale
25. A pharmacokinetic interaction between carbamazepine and olanzapine: Observations on possible mechanism
26. An interaction between carbamazepine and fluvoxamine
27. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers
28. Montgomery-Åsberg severity gradations
29. Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects
30. A new depression scale designed to be sensitive to change
31. Escitalopram (S-enantiomer of citalopram): Clinical efficacy and onset of action predicted from a rat model
32. Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus
33. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes
34. Citalopram: A comprehensive review
35. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
36. Prevalence, recognition, and treatment of comorbid depression and anxiety
37. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes
38. Stereoselective biotransformation of the selective serotonin reuptake inhibitor, citalopram, and its demethylated metabolites by monoamine oxidases in human liver
39. Mood-stabilizing drugs in depression
40. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms
41. Practical guidelines for combination drug therapy of treatment-resistant depression
42. The effect of carbamazepine on the 2-hydroxylation of desipramine
43. Plasma concentrations of risperidone and 9-hydroxyrisperidone. effect of comedication with carbamazepine or valproate
44. Carbamazepine coadministration with fluoxetine or fluvoxamine
45. Clinically significant pharmacokinetic drug interactions with carbamazepine-an update [review]
46. Chiral switches
47. Escitalopram (S-Citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram
48. The effect of citalopram in panic disorder
49. Antidepressants in panic disorder
50. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors